WADA Prohibition While GLP1 and cagrilintide individually have not been explicitly listed by WADA, several considerations apply: GLP-1 agonist precedent Other GLP-1 agonists are monitored for potential misuse in athletics Weight-class sports concern Rapid weight reduction capabilities raise concerns for sports with weight classifications Performance-enhancing potential Metabolic effects could theoretically affect athletic performance Monitoring program possible May be added to WADA monitoring program as use increases Athletes should consult with their sports governing bodies and anti-doping authorities before considering any GLP-1 or amylin analogue use
Our experts review the latest clinical data and design precision-based plans for cognitive and metabolic performance
Selling unauthorized drugs is illegal in Canada, Health Canada said in a public advisory that warned their usage could cause infection, allergic reactions, and other poor outcomes, contain high-risk ingredients, additives, or contaminants and potentially interact with other medications
Many patients report feeling more energetic after receiving these injections, which can help them stay active and maintain their exercise routines
Non-alcoholic fatty liver disease and risk of incident type 2 diabetes: role of circulating branched-chain amino acids
